Author:
Dy Grace K.,Suri Ajit,Reid Joel M.,Sloan Jeff A.,Pitot Henry C.,Alberts Steven R.,Goldberg Richard M.,Atherton Pamela J.,Hanson Lorelei J.,Burch Patrick A.,Rubin Joseph,Erlichman Charles,Adjei Alex A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference23 articles.
1. Plunkett W, Huang P, Xu YZ, et al (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22 [Suppl 11]:3–10
2. Shih C, Chen VJ, Gossett LS, et al (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116–1123
3. Rusthoven J, Eisenhauer E, Butts C, et al (1999) Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 17:1194–1199
4. Clarke S, Millward M, Findlay M, et al (1998) Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC). Ann Oncol 9 [Suppl 4]:86
5. John W, Picus J, Blanke C, et al (2000) Multitargeted antifolate (pemetrexed disodium, LY231514) activity in patients with advanced colorectal cancer: results from a phase II study. Cancer 88:1807–1813
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献